ISLT News Alert One E-Commerce Corp (ISLT) 0.2500 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
One E-Commerce Corp (ISLT) 0.2500 $ISLT

Islet Sciences and BHV Pharma Enter Into Merger Agreement; Combined Company to be Named Avogenx, Inc.
GlobeNewswire - Wed Oct 01, 9:21AM CDT
Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences" , a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, and Brighthaven Ventures, L.L.C., d/b/a BHV Pharma ("BHV" , a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate ("remogliflozin" for type 2 diabetes and non-alcoholic steatohepatitis ("NASH" , jointly announced today that, consistent with the letter of intent entered into by Islet Sciences and BHV on March 12, 2014, they have entered into a merger agreement that will combine the operations and development pipelines of the two companies. Upon closing of the acquisition of BHV, the combined organization will be named Avogenx, Inc. ("Avogenx" and will continue to operate under the leadership of the current Islet Sciences management.

Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors
GlobeNewswire - Wed Aug 06, 7:00AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Lisofylline Analogs and Methods for Use." The new patent (U.S #13/477,613) will extend coverage to include a significantly broader gamut of chemical compounds, which Islet may develop as immune-modulating drugs targeting an inflammatory pathway involved in a number important diseases, including diabetes and nonalcoholic steatohepatitis (NASH).

Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that its collaborators at the Yale University School of Medicine have published key data highlighting the efficacy of Islet's novel diabetes diagnostic in Endocrinology, the journal of the Endocrine Society. The study demonstrated improved detection of beta-cell loss, a key biomarker of diabetes progression, using a novel technology called droplet digital PCR (ddPCR).

Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
PR Newswire - Mon Jun 23, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), as a novel treatment for non-alcoholic steatohepatitis (NASH) and its precursor, non-alcoholic fatty liver disease (NAFLD). The poster was presented this past Saturday at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.

Islet Sciences, Inc. to Present at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014
PR Newswire - Wed Jun 18, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, will present a peer-reviewed poster relating to its highly selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.

Islet Sciences, Inc. Presents Positive Clinical Results for Best-in-Class SGLT2 Inhibitor at American Diabetes Association (ADA) Annual Meeting
PR Newswire - Mon Jun 16, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, presented final results from its two Phase 2b clinical studies evaluating remogliflozin etabonate (a prodrug of remogliflozin, the active inhibitor) at the 74th American Diabetes Association (ADA) Annual Scientific Sessions, showing that the differentiated sodium glucose co-transporter 2 (SGLT2) inhibitor demonstrated a potential best-in-class safety and efficacy profile, when dosed once-daily or twice-daily, respectively. Positive Phase 1 results were also presented for the company's novel once-daily biphasic formulation of remogliflozin etabonate, which achieved targeted pharmacokinetic and pharmacodynamic profiles, successfully combining the best-in-class properties of previous formulations.

Islet Sciences, Inc. to Present at American Diabetes Association (ADA)
PR Newswire - Thu Jun 12, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the treatment and diagnosis of metabolic disease, announced today it will present three peer-reviewed posters relating to its differentiated sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, at the 74th American Diabetes Association (ADA) Scientific Sessions at the Moscone Center in San Francisco, June 13-17.

Islet Sciences to Host Conference Call to Discuss Acquisition of BHV Pharma
Marketwire - Mon Mar 17, 8:30AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced that on Monday, March 17, 2014, the Company will host a conference call to discuss the announced acquisition of BHV Pharma. The call is scheduled to take place at 4:15 p.m. ET.

Islet Sciences appoints Dr. Michael Luther to board
M2 - Mon Mar 17, 7:55AM CDT
US-based biopharmaceutical company Islet Sciences (OTCQB:ISLT) revealed on Friday the addition of Dr. Michael Luther to its board of directors.

Islet Sciences Appoints Michael Luther, Ph.D., MBA to Board of Directors
Marketwire - Fri Mar 14, 8:10AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced the appointment of Dr. Michael Luther, Senior Vice President of Discovery and Development at Albany Molecular Research, Inc. to Islet's Board of Directors.

Islet Sciences to buy BHV Pharma, including Phase two SGLT2 inhibitor remogliflozin etabonate for Type 2 diabetes and NASH
M2 - Fri Mar 14, 4:10AM CDT
Biopharmaceutical company Islet Sciences (OTCBB:ISLT) (OTCQB:ISLT) said on Thursday that it has entered into a binding letter of intent to acquire Brighthaven Ventures /BHV Pharma (BHV), including the remogliflozin programme.

Islet Sciences to Acquire BHV Pharma and Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate Indicated for Type 2 Diabetes and NASH
Marketwire - Thu Mar 13, 8:15AM CDT
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that it has signed a binding letter of intent to acquire Brighthaven Ventures, LLC d/b/a BHV Pharma ("BHV" . BHV is a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate ("remogliflozin" for type 2 diabetes and non-alcoholic steatohepatitis ("NASH" . Remogliflozin is currently in phase 2 clinical development.

CORWIL Technology Corporation Completes Asset Purchase Of VIKO Test Labs
PR Newswire - Mon Mar 10, 10:01PM CDT
CORWIL Technology Corporation ("CORWIL" has announced the asset purchase of VIKO Test Labs, a division of Infiniti Solutions. The addition of electrical, environmental, and mechanical test services enhances CORWIL's market position as a true OSAT (Outsourced Semiconductor Assembly & Test) leader, joining an exclusive list of domestic providers with both assembly and test operations located in the United States.

Islet Holdings Files Amended Complaint Against Islet Sciences
GlobeNewswire - Fri Aug 02, 2:56PM CDT
According to Islet Holdings, new allegations of conspiracy and racketeering and a written confession from a scheme participant have led to the resignation of CEO John Steel and the restructuring of the management team at Islet Sciences, Inc. (OTCBB:ISLT). The restructuring was announced after an amended complaint was filed in federal court charging that Islet Sciences has been enticing investments using false documents, and that Steel has "made numerous threats against anyone related to Isletech."

Islet Sciences Begins Restructuring of Company's Senior Management and Board of Directors
Business Wire - Tue Jul 16, 3:51PM CDT
Islet Sciences, Inc., (OTCBB:ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, today announced changes to the company's senior management team and the board of directors.

Islet Sciences Chief Scientific Officer to Present Scientific Studies at Upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy
Business Wire - Mon Jul 08, 8:44AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, will be presenting several scientific presentations at the upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy July 7-11, 2013.

Islet Sciences Chief Scientific Officer Receives $1.27 million in Grant from JDRF to Create Innovative Diabetes Treatments
Business Wire - Thu Jun 27, 3:02PM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, has received $1.27 million in grant funding from the JDRF to develop innovative methods to treat and possibly cure type 1 diabetes. Dr. Jerry Nadler, Dr. Elliot Botvinick and Dr. Paul Johnson, co-investigators in the JDRF grant, are also members of the Company's Scientific Advisory Board.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 96

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 80

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 103

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 85

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 59

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 59

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Fly Play hf. Amid Takeover Talks

Updated Category News Views 224

Understanding the Recent Developments at Fly Play hf. Fly Play hf. is currently navigating through a significant phase in its operational journey. Amid potential takeover discussions, stakeholders are keenly interested in how such a move could reshape the airline's direction. As the aviation industry continues to evolve, Fly Play's adaptability and innovative strategies...

Continue Reading
AvePoint Aims for Dual Listing at Singapore Exchange

Updated Category News Views 275

AvePoint's Ambitious Step Towards Dual Listing AvePoint (Nasdaq: AVPT), renowned as a leader in data security, governance, and resilience, is taking a significant step forward by submitting an application to list its shares on the Singapore Exchange Securities Trading Limited (SGX-ST). This application is set against the backdrop of its existing presence on the Nasdaq...

Continue Reading
Kris Kehl Joins Planet Home Lending to Enhance Services

Updated Category News Views 140

Kris Kehl Joins Planet Home Lending Team Planet Home Lending, a prominent national mortgage lender, is excited to announce the addition of Kris Kehl as a Senior Mortgage Loan Officer in California. With over 22 years of extensive experience in the mortgage industry, Kehl brings a relationship-first approach that prioritizes accessibility, clear communication, and...

Continue Reading
The S&P 500: Understanding Future Market Return Challenges

Updated Category News Views 647

Understanding Future Returns for the S&P 500 Recently, there’s been a surge of interest regarding predictions for future returns of the S&P 500. With insights from financial giants like J.P. Morgan and Goldman Sachs indicating a significantly lower return forecast for the coming decade, it’s essential to delve deeper into these evaluations. The consistent message has...

Continue Reading
Investors Can Seize Winds of Change with enCore Energy

Updated Category News Views 183

Understanding the Opportunity with enCore Energy Corp. Investors are currently presented with a significant opportunity to engage in the ongoing developments at enCore Energy Corp. (NASDAQ: EU). The global landscape is rapidly changing, especially in the energy sector, and enCore is no exception. A class action has been filed on behalf of shareholders who purchased...

Continue Reading